stockportfolio.pro
Stocks / DMRA vs INBX
DMRA vs INBX
Damora Therapeutics, Inc. and Inhibrx Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Damora Therapeutics, Inc. (DMRA) | Inhibrx Biosciences, Inc. (INBX) | |
|---|---|---|
| Market cap | $1.3B | $1.3B |
| Revenue (latest FY) | $0 | $1.30M |
| Net income (latest FY) | $-209.84M | $-140.06M |
| Revenue growth (5y CAGR) | — | -0.0% |
| Net margin | — | -10773.5% |
| Return on equity | -87.3% | -1752.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DMRA — free Open INBX — freeFrequently asked questions
Which is bigger, DMRA or INBX?
Inhibrx Biosciences, Inc. is larger by market capitalization — $1.3B versus $1.3B.
Which grows faster, DMRA or INBX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.